Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3339283

CC1(C)CCC(NC2Cc3ccc(-c4cccc(C(N)=O)c4)cc3C2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.43
DPP7 Q9UHL4 2/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
TDP2 O95551 1/20 0.41
PDK2 Q15119 1/20 0.40
CCR6 P51684 1/20 0.39
FAAH O00519 3/20 0.38
CCNE2 O96020 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
TRPA1 O75762 1/20 0.37
EPHX2 P34913 1/20 0.37
FAAH2 Q6GMR7 1/20 0.37
MGLL Q99685 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
IDH1 O75874 1/20 0.36
ADRB3 P13945 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1786427 0.93 TDP2 (0.46) TDP2PDK2FAAHTRPA1EPHX2
SCHEMBL3339287 0.80 GRIA2 (0.46) HDAC6CCR2GRIA2
Trifluoroacetic Acid SCHEMBL3338278 0.80 OPRM1 (0.50) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3342749 0.79 DPP4 (0.55) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3339763 0.79 DPP4 (0.55) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3340025 0.78 OPRM1 (0.47) DPP4DPP7DPP8DPP9CCR6
Trifluoroacetic Acid SCHEMBL3341720 0.78 DPP4 (0.44) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3340014 0.77 CTSC (0.44) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3339667 0.77 DPP4 (0.42) DPP4DPP7DPP8DPP9PDK2
Trifluoroacetic Acid SCHEMBL3337465 0.77 DPP4 (0.42) DPP4DPP7DPP8DPP9PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 DPP4 1431/4885DPP7 1333/4885DPP8 2313/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 DPP4 1228/4885DPP7 1096/4885DPP8 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.